Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B G Ward

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
International Journal of Cancer|May 14, 1998
Peritoneal fluid from ovarian cancer patients stimulates MUC1 epithelial mucin expression in ovarian cancer cell linesD J Munster, R J Quin, A S Bansal, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 28, 1993
Circulating tumour-associated mucin concentrations, determined by the CASA assay, in healthy womenM A McGuckin, L E Ramm, G J Joy, et al.
Cancer|September 15, 1993
Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patientsP L Devine, M A McGuckin, L E Ramm, et al.
Gynecologic Oncology|July 2, 1998
No evidence for microsatellite instability from allelotype analysis of benign and low malignant potential ovarian neoplasmsY C Shih, J Kerr, T G Hurst, et al.
The Australian & New Zealand Journal of Obstetrics & Gynaecology|May 1, 1991
A clinicopathological study of adenocarcinoma in situ of the cervix. The influence of cervical HPV infection and other factors, and the role of conservative surgeryJ L Nicklin, R G Wright, J R Bell, et al.
Gynecologic Oncology|May 1, 1990
Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125M A McGuckin, G T Layton, M J Bailey, et al.
Cancer|January 15, 1993
The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assaysB G Ward, M A McGuckin, L E Ramm, et al.
Cancer Immunology, Immunotherapy : CII|August 5, 1998
Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy womenE R Richards, P L Devine, R J Quin, et al.
British Journal of Obstetrics and Gynaecology|February 1, 1987
Tumour-associated monoclonal antibodies for the diagnosis and assessment of ovarian cancerJ H Shepherd, M Granowska, K E Britton, et al.
Nuclear Medicine Communications|March 1, 1989
Therapeutic considerations in the use of intraperitoneal radiolabelled monoclonal antibodies in ovarian carcinomaM E Crowther, B G Ward, M Granowska, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
International Journal of Cancer|May 14, 1998
Peritoneal fluid from ovarian cancer patients stimulates MUC1 epithelial mucin expression in ovarian cancer cell linesD J Munster, R J Quin, A S Bansal, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|February 28, 1993
Circulating tumour-associated mucin concentrations, determined by the CASA assay, in healthy womenM A McGuckin, L E Ramm, G J Joy, et al.
Cancer|September 15, 1993
Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patientsP L Devine, M A McGuckin, L E Ramm, et al.
Gynecologic Oncology|July 2, 1998
No evidence for microsatellite instability from allelotype analysis of benign and low malignant potential ovarian neoplasmsY C Shih, J Kerr, T G Hurst, et al.
The Australian & New Zealand Journal of Obstetrics & Gynaecology|May 1, 1991
A clinicopathological study of adenocarcinoma in situ of the cervix. The influence of cervical HPV infection and other factors, and the role of conservative surgeryJ L Nicklin, R G Wright, J R Bell, et al.
Gynecologic Oncology|May 1, 1990
Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125M A McGuckin, G T Layton, M J Bailey, et al.
Cancer|January 15, 1993
The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assaysB G Ward, M A McGuckin, L E Ramm, et al.
Cancer Immunology, Immunotherapy : CII|August 5, 1998
Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy womenE R Richards, P L Devine, R J Quin, et al.
British Journal of Obstetrics and Gynaecology|February 1, 1987
Tumour-associated monoclonal antibodies for the diagnosis and assessment of ovarian cancerJ H Shepherd, M Granowska, K E Britton, et al.
Nuclear Medicine Communications|March 1, 1989
Therapeutic considerations in the use of intraperitoneal radiolabelled monoclonal antibodies in ovarian carcinomaM E Crowther, B G Ward, M Granowska, et al.
Pageof 6